Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

219 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Descriptive analysis of seizures and comorbidities associated with fragile X syndrome.
Albizua I, Charen K, Shubeck L, Talboy A, Berry-Kravis E, Kaufmann WE, Stallworth JL, Drazba KT, Erickson CA, Sweeney JA, Tartaglia N, Warren SF, Hagerman R, Sherman SL, Warren ST, Jin P, Allen EG. Albizua I, et al. Among authors: kaufmann we. Mol Genet Genomic Med. 2022 Aug;10(8):e2001. doi: 10.1002/mgg3.2001. Epub 2022 Jul 18. Mol Genet Genomic Med. 2022. PMID: 35852003 Free PMC article.
Newborn, carrier, and early childhood screening recommendations for fragile X.
Abrams L, Cronister A, Brown WT, Tassone F, Sherman SL, Finucane B, McConkie-Rosell A, Hagerman R, Kaufmann WE, Picker J, Coffey S, Skinner D, Johnson V, Miller R, Berry-Kravis E. Abrams L, et al. Among authors: kaufmann we. Pediatrics. 2012 Dec;130(6):1126-35. doi: 10.1542/peds.2012-0693. Epub 2012 Nov 5. Pediatrics. 2012. PMID: 23129072 Review.
Arbaclofen in fragile X syndrome: results of phase 3 trials.
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL. Berry-Kravis E, et al. Among authors: kaufmann we. J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. eCollection 2017. J Neurodev Disord. 2017. PMID: 28616094 Free PMC article.
Fragile X targeted pharmacotherapy: lessons learned and future directions.
Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati EV, Sweeney JA, Fitzpatrick SE, Brown WT, Budimirovic D, Hagerman RJ, Hessl D, Kaufmann WE, Berry-Kravis E. Erickson CA, et al. Among authors: kaufmann we. J Neurodev Disord. 2017 Jun 12;9:7. doi: 10.1186/s11689-017-9186-9. eCollection 2017. J Neurodev Disord. 2017. PMID: 28616096 Free PMC article. Review.
Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.
Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, King MK, Abbeduto L, Kaufmann WE. Budimirovic DB, et al. Among authors: kaufmann we. J Neurodev Disord. 2017 Jun 12;9:14. doi: 10.1186/s11689-017-9193-x. eCollection 2017. J Neurodev Disord. 2017. PMID: 28616097 Free PMC article. Review.
219 results